Hubbry Logo
Gut microbiotaGut microbiotaMain
Open search
Gut microbiota
Community hub
Gut microbiota
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Gut microbiota
Gut microbiota
from Wikipedia

Escherichia coli, one of the many species of bacteria present in the human gut

Gut microbiota, gut microbiome, or gut flora are the microorganisms, including bacteria, archaea, fungi, and viruses, that live in the digestive tracts of animals.[1][2] The gastrointestinal metagenome is the aggregate of all the genomes of the gut microbiota.[3][4] The gut is the main location of the human microbiome.[5] The gut microbiota has broad impacts, including effects on colonization, resistance to pathogens, maintaining the intestinal epithelium, metabolizing dietary and pharmaceutical compounds, controlling immune function, and even behavior through the gut–brain axis.[4]

The microbial composition of the gut microbiota varies across regions of the digestive tract. The colon contains the highest microbial density of any human-associated microbial community studied so far, representing between 300 and 1000 different species.[6] Bacteria are the largest and to date, best studied component and 99% of gut bacteria come from about 30 or 40 species.[7] About 55% of the dry mass of feces is bacteria.[8] Over 99% of the bacteria in the gut are anaerobes, but in the cecum, aerobic bacteria reach high densities.[5] It is estimated that the human gut microbiota has around a hundred times as many genes as there are in the human genome.

Overview

[edit]
Composition and distribution of gut microbiota in human body

In humans, the gut microbiota has the highest numbers and species of bacteria compared to other areas of the body.[9] The approximate number of bacteria composing the gut microbiota is about 1013–1014 (10,000 to 100,000 billion).[10] In humans, the gut flora is established at birth and gradually transitions towards a state resembling that of adults by the age of two,[11] coinciding with the development and maturation of the intestinal epithelium and intestinal mucosal barrier. This barrier is essential for supporting a symbiotic relationship with the gut flora while providing protection against pathogenic organisms.[12][13]

The relationship between some gut microbiota and humans is not merely commensal (a non-harmful coexistence), but rather a mutualistic relationship.[5]: 700  Some human gut microorganisms benefit the host by fermenting dietary fiber into short-chain fatty acids (SCFAs), such as acetic acid and butyric acid, which are then absorbed by the host.[9][14] Intestinal bacteria also play a role in synthesizing certain B vitamins and vitamin K as well as metabolizing bile acids, sterols, and xenobiotics.[5][14] The systemic importance of the SCFAs and other compounds they produce are like hormones and the gut flora itself appears to function like an endocrine organ.[14] Dysregulation of the gut flora has been correlated with a host of inflammatory and autoimmune conditions.[9][15]

The composition of human gut microbiota changes over time, when the diet changes, and as overall health changes.[9][15] A systematic review from 2016 examined the preclinical and small human trials that have been conducted with certain commercially available strains of probiotic bacteria and identified those that had the most potential to be useful for certain central nervous system disorders.[16] It should also be highlighted that the Mediterranean diet, rich in vegetables and fibers, stimulates the activity and growth of beneficial bacteria for the brain.[17]

Classifications

[edit]

The microbial composition of the gut microbiota varies across the digestive tract. In the stomach and small intestine, relatively few species of bacteria are generally present.[6][18] Fungi, protists, archaea, and viruses are also present in the gut flora, but less is known about their activities.[19]

Candida albicans, a yeast found in the gut

Many species in the gut have not been studied outside of their hosts because they cannot be cultured.[18][7][20] While there are a small number of core microbial species shared by most individuals, populations of microbes can vary widely.[21] Within an individual, their microbial populations stay fairly constant over time, with some alterations occurring due to changes in lifestyle, diet and age.[6][22] The Human Microbiome Project has set out to better describe the microbiota of the human gut and other body locations.[citation needed]

The four dominant bacterial phyla in the human gut are Bacillota (Firmicutes), Bacteroidota, Actinomycetota, and Pseudomonadota.[23] Most bacteria belong to the genera Bacteroides, Clostridium, Faecalibacterium,[6][7] Eubacterium, Ruminococcus, Peptococcus, Peptostreptococcus, and Bifidobacterium.[6][7] Other genera, such as Escherichia and Lactobacillus, are present to a lesser extent.[6] Species from the genus Bacteroides alone constitute about 30% of all bacteria in the gut, suggesting that this genus is especially important in the functioning of the host.[18]

Fungal genera that have been detected in the gut include Candida, Saccharomyces, Aspergillus, Penicillium, Rhodotorula, Trametes, Pleospora, Sclerotinia, Bullera, and Galactomyces, among others.[24][25] Rhodotorula is most frequently found in individuals with inflammatory bowel disease while Candida is most frequently found in individuals with hepatitis B cirrhosis and chronic hepatitis B.[24]

Archaea constitute another large class of gut flora which are important in the metabolism of the bacterial products of fermentation.

Industrialization is associated with changes in the microbiota and the reduction of diversity could drive certain species to extinction; in 2018, researchers proposed a biobank repository of human microbiota.[26]

Enterotype

[edit]

An enterotype is a classification of living organisms based on its bacteriological ecosystem in the human gut microbiome not dictated by age, gender, body weight, or national divisions.[27] There are indications that long-term diet influences enterotype.[28] Three human enterotypes have been proposed,[27][29] but their value has been questioned.[30]

Composition

[edit]
Diagram of human gastrointestinal tract microbiota depicted in various regions

Bacteria

[edit]

Stomach

[edit]

Due to the high acidity of the stomach, most microorganisms cannot survive there. The main bacteria of the gastric microbiota belong to five major phyla: Firmicutes, Bacteroidetes, Actinobacteria, Fusobacteriota, and Proteobacteria. The dominant genera are Prevotella, Streptococcus, Veillonella, Rothia, and Haemophilus.[31] The interaction between the pre-existing gastric microbiota with the introduction of H. pylori may influence disease progression.[31] When there is a presence of H. pylori it becomes the dominant species of the microbiota.[32]

Intestines

[edit]
Bacteria commonly found in the human colon[33]
Bacterium Incidence (%)
Bacteroides fragilis 100
Bacteroides melaninogenicus 100
Bacteroides oralis 100
Enterococcus faecalis 100
Escherichia coli 100
Enterobacter sp. 40–80
Klebsiella sp. 40–80
Bifidobacterium bifidum 30–70
Staphylococcus aureus 30–50
Lactobacillus 20–60
Clostridium perfringens 25–35
Proteus mirabilis 5–55
Clostridium tetani 1–35
Clostridium septicum 5–25
Pseudomonas aeruginosa 3–11
Salmonella enterica 3–7
Faecalibacterium prausnitzii ?common
Peptostreptococcus sp. ?common
Peptococcus sp. ?common

The small intestine contains a trace amount of microorganisms due to the proximity and influence of the stomach. Gram-positive cocci and rod-shaped bacteria are the predominant microorganisms found in the small intestine.[5] However, in the distal portion of the small intestine alkaline conditions support gram-negative bacteria of the Enterobacteriaceae.[5] The bacterial flora of the small intestine aid in a wide range of intestinal functions. The bacterial flora provide regulatory signals that enable the development and utility of the gut. Overgrowth of bacteria in the small intestine can lead to intestinal failure.[34] In addition the large intestine contains the largest bacterial ecosystem in the human body.[5] About 99% of the large intestine and feces flora are made up of obligate anaerobes such as Bacteroides and Bifidobacterium.[35] Factors that disrupt the microorganism population of the large intestine include antibiotics, stress, and parasites.[5]

Bacteria make up most of the flora in the colon[36] and account for 60% of fecal nitrogen.[6] This fact makes feces an ideal source of gut flora for any tests and experiments by extracting the nucleic acid from fecal specimens, and bacterial 16S rRNA gene sequences are generated with bacterial primers. This form of testing is also often preferable to more invasive techniques, such as biopsies.

Five phyla dominate the intestinal microbiota: Bacteroidota, Bacillota (Firmicutes), Actinomycetota, Pseudomonadota, and Verrucomicrobiota – with Bacteroidota and Bacillota constituting 90% of the composition.[37] Somewhere between 300[6] and 1000 different species live in the gut,[18] with most estimates at about 500.[38][39] However, it is probable that 99% of the bacteria come from about 30 or 40 species, with Faecalibacterium prausnitzii (phylum firmicutes) being the most common species in healthy adults.[7][40]

Research suggests that the relationship between gut flora and humans is not merely commensal (a non-harmful coexistence), but rather is a mutualistic, symbiotic relationship.[18] Though people can survive with no gut flora,[38] the microorganisms perform a host of useful functions, such as fermenting unused energy substrates, training the immune system via end products of metabolism like propionate and acetate, preventing growth of harmful species, regulating the development of the gut, producing vitamins for the host (such as biotin and vitamin K), and producing hormones to direct the host to store fats.[5] Extensive modification and imbalances of the gut microbiota and its microbiome or gene collection are associated with obesity.[41] However, in certain conditions, some species are thought to be capable of causing disease by causing infection or increasing cancer risk for the host.[6][36]

Fungi

[edit]

Fungi also make up a part of the gut flora, but less is known about their activities.[42]

Due to the prevalence of fungi in the natural environment, determining which genera and species are permanent members of the gut mycobiome is difficult.[43][44] Research is underway as to whether Penicillium is a permanent or transient member of the gut flora, obtained from dietary sources such as cheese, though several species in the genus are known to survive at temperatures around 37 °C, about the same as the core body temperature.[44] Saccharomyces cerevisiae, brewer's yeast, is known to reach the intestines after being ingested and can be responsible for the condition auto-brewery syndrome in cases where it is overabundant,[44][45][46] while Candida albicans is likely a permanent member, and is believed to be acquired at birth through vertical transmission.[47][medical citation needed]

Viruses

[edit]

The human virome includes all viruses associated with the human body, ranging from viruses that infect native cells to bacteriophages that infect bacteria in the microbiome. Among these, bacteriophages are by far the most numerous.[48]

Variation

[edit]

Age

[edit]

There are common patterns of microbiome composition evolution during life.[49] In general, the diversity of microbiota composition of fecal samples is significantly higher in adults than in children, although interpersonal differences are higher in children than in adults.[50] Much of the maturation of microbiota into an adult-like configuration happens during the first three years of life.[50]

As the microbiome composition changes, so does the composition of bacterial proteins produced in the gut. In adult microbiomes, a high prevalence of enzymes involved in fermentation, methanogenesis and the metabolism of arginine, glutamate, aspartate and lysine have been found. In contrast, in infant microbiomes the dominant enzymes are involved in cysteine metabolism and fermentation pathways.[50]

Geography

[edit]

Gut microbiome composition depends on the geographic origin of populations. Variations in a trade-off of Prevotella, the representation of the urease gene, and the representation of genes encoding glutamate synthase/degradation or other enzymes involved in amino acids degradation or vitamin biosynthesis show significant differences between populations from the US, Malawi, or Amerindian origin.[50]

The US population has a high representation of enzymes encoding the degradation of glutamine and enzymes involved in vitamin and lipoic acid biosynthesis; whereas Malawi and Amerindian populations have a high representation of enzymes encoding glutamate synthase and they also have an overrepresentation of α-amylase in their microbiomes. As the US population has a diet richer in fats than Amerindian or Malawian populations which have a corn-rich diet, the diet is probably the main determinant of the gut bacterial composition.[50]

Further studies have indicated a large difference in the composition of microbiota between European and rural African children. The fecal bacteria of children from Florence were compared to that of children from the small rural village of Boulpon in Burkina Faso. The diet of a typical child living in this village is largely lacking in fats and animal proteins and rich in polysaccharides and plant proteins. The fecal bacteria of European children were dominated by Firmicutes and showed a marked reduction in biodiversity, while the fecal bacteria of the Boulpon children was dominated by Bacteroidetes. The increased biodiversity and different composition of the gut microbiome in African populations may aid in the digestion of normally indigestible plant polysaccharides and also may result in a reduced incidence of non-infectious colonic diseases.[51]

On a smaller scale, it has been shown that sharing numerous common environmental exposures in a family is a strong determinant of individual microbiome composition. This effect has no genetic influence and it is consistently observed in culturally different populations.[50]

Malnourishment

[edit]

Malnourished children have less mature and less diverse gut microbiota than healthy children, and changes in the microbiome associated with nutrient scarcity can in turn be a pathophysiological cause of malnutrition.[52][53] Malnourished children also typically have more potentially pathogenic gut flora, and more yeast in their mouths and throats.[54] Altering diet may lead to changes in gut microbiota composition and diversity.[55]

Race and ethnicity

[edit]

Researchers with the American Gut Project and Human Microbiome Project found that twelve microbe families varied in abundance based on the race or ethnicity of the individual. The strength of these associations is limited by the small sample size: the American Gut Project collected data from 1,375 individuals, 90% of whom were white.[56] The Healthy Life in an Urban Setting (HELIUS) study in Amsterdam found that those of Dutch ancestry had the highest level of gut microbiota diversity, while those of South Asian and Surinamese descent had the lowest diversity. The study results suggested that individuals of the same race or ethnicity have more similar microbiomes than individuals of different racial backgrounds.[56]

Socioeconomic status

[edit]

As of 2020, at least two studies have demonstrated a link between an individual's socioeconomic status (SES) and their gut microbiota. A study in Chicago found that individuals in higher SES neighborhoods had greater microbiota diversity. People from higher SES neighborhoods also had more abundant Bacteroides bacteria. Similarly, a study of twins in the United Kingdom found that higher SES was also linked with a greater gut diversity.[56]

Antibiotic use

[edit]

As of 2023, a study suggests that antibiotics, especially those used in the treatment of broad-spectrum bacterial infections, have negative effects on the gut microbiota.[57] The study also states that there are many experts on intestinal health concerned that antibody usage has reduced the diversity of the gut microbiota, many of the strains are lost, and if there is a re-emergence of the bacteria, is gradual and long-term.[57]

Functions

[edit]

When the study of gut flora began in 1995,[58] it was thought to have three key roles: direct defense against pathogens, fortification of host defense by its role in developing and maintaining the intestinal epithelium and inducing antibody production there, and metabolizing otherwise indigestible compounds in food. Subsequent work discovered its role in training the developing immune system, and yet further work focused on its role in the gut–brain axis.[59] The gut microbiota not only influences intestinal health but also plays a role in systemic immune regulation, including interactions with the pulmonary immune environment through what is known as the 'gut–lung axis'.[60]

Direct inhibition of pathogens

[edit]

The gut flora community plays a direct role in defending against pathogens by fully colonising the space, making use of all available nutrients, and by secreting compounds known as cytokines that kill or inhibit unwelcome organisms that would compete for nutrients with it.[61] Different strains of gut bacteria cause the production of different cytokines. Cytokines are chemical compounds produced by our immune system for initiating the inflammatory response against infections. Disruption of the gut flora allows competing organisms like Clostridioides difficile to become established that otherwise are kept in abeyance.[61]

Development of enteric protection and immune system

[edit]
Microfold cells transfer antigens (Ag) from the lumen of the gut to gut-associated lymphoid tissue (GALT) via transcytosis and present them to different innate and adaptive immune cells.

Gut flora in infants becomes similar to an adult within one to two years of birth.[12] As the gut flora establishes, the lining of the intestines – the intestinal epithelium and the intestinal mucosal barrier that it secretes – develop a symbiosis with microorganisms.[12] Specifically, goblet cells that produce the mucosa proliferate, and the mucosa layer thickens, providing an outside mucosal layer in which favorable microorganisms can anchor and feed, and an inner layer that these organisms cannot penetrate.[12][13] Additionally, the development of gut-associated lymphoid tissue (GALT), which forms part of the intestinal epithelium and which detects and reacts to pathogens, develops during the time that the gut flora becomes established.[12] The GALT that develops is tolerant to gut flora species, but not to other microorganisms.[12] GALT also normally becomes tolerant to food the infant consumes, and the gut flora metabolites (molecules formed from metabolism) produced from food.[12]

The human immune system creates cytokines that can drive the immune system to produce inflammation in order to protect itself, and that can tamp down the immune response to maintain homeostasis and allow healing after insult or injury.[12] Different bacterial species that appear in gut flora have been shown to be able to drive the immune system to create cytokines selectively; for example Bacteroides fragilis and some Clostridia species appear to drive an anti-inflammatory response, while some segmented filamentous bacteria drive the production of inflammatory cytokines.[12][62] Gut flora can also regulate the production of antibodies by the immune system.[12][63] One function of this regulation is to cause B cells to class switch to IgA. In most cases B cells need activation from T helper cells to induce class switching; however, in another pathway, gut flora cause NF-kB signaling by intestinal epithelial cells which results in further signaling molecules being secreted.[64] These signaling molecules interact with B cells to induce class switching to IgA.[64] IgA is an important type of antibody that is used in mucosal environments like the gut. It has been shown that IgA can help diversify the gut community and helps in getting rid of bacteria that cause inflammatory responses.[65] Ultimately, IgA maintains a healthy environment between the host and gut bacteria.[65] These cytokines and antibodies can have effects outside the gut, in the lungs and other tissues.[12]

A 2022 review indicated that various mechanisms are under preliminary research to assess how gut microbes may modulate vaccine immunogenicity, including effects on antigen presentation and cytokine profiles.[66]

Metabolism

[edit]
Tryptophan metabolism by human gut microbiota ()
The image above contains clickable links
This diagram shows the biosynthesis of bioactive compounds (indole and certain other derivatives) from tryptophan by bacteria in the gut.[67] Indole is produced from tryptophan by bacteria that express tryptophanase.[67] Clostridium sporogenes metabolizes tryptophan into indole and subsequently 3-indolepropionic acid (IPA),[68] a highly potent neuroprotective antioxidant that scavenges hydroxyl radicals.[67][69][70] IPA binds to the pregnane X receptor (PXR) in intestinal cells, thereby facilitating mucosal homeostasis and barrier function.[67] Following absorption from the intestine and distribution to the brain, IPA confers a neuroprotective effect against cerebral ischemia and Alzheimer's disease.[67] Lactobacillaceae (Lactobacillus s.l.) species metabolize tryptophan into indole-3-aldehyde (I3A) which acts on the aryl hydrocarbon receptor (AhR) in intestinal immune cells, in turn increasing interleukin-22 (IL-22) production.[67] Indole itself triggers the secretion of glucagon-like peptide-1 (GLP-1) in intestinal L cells and acts as a ligand for AhR.[67] Indole can also be metabolized by the liver into indoxyl sulfate, a compound that is toxic in high concentrations and associated with vascular disease and renal dysfunction.[67] AST-120 (activated charcoal), an intestinal sorbent that is taken by mouth, adsorbs indole, in turn decreasing the concentration of indoxyl sulfate in blood plasma.[67]

Without gut flora, the human body would be unable to utilize some of the undigested carbohydrates it consumes, because some types of gut flora have enzymes that human cells lack for breaking down certain polysaccharides.[14] Rodents raised in a sterile environment and lacking in gut flora need to eat 30% more calories just to remain the same weight as their normal counterparts.[14] Carbohydrates that humans cannot digest without bacterial help include certain starches, fiber, oligosaccharides, and sugars that the body failed to digest and absorb like lactose in the case of lactose intolerance and sugar alcohols, mucus produced by the gut, and proteins.[9][14]

Bacteria turn carbohydrates they ferment into short-chain fatty acids by a form of fermentation called saccharolytic fermentation.[39] Products include acetic acid, propionic acid and butyric acid.[7][39] These materials can be used by host cells, providing a major source of energy and nutrients.[39] Gases (which are involved in signaling[71] and may cause flatulence) and organic acids, such as lactic acid, are also produced by fermentation.[7] Acetic acid is used by muscle, propionic acid facilitates liver production of ATP, and butyric acid provides energy to gut cells.[39]

Gut flora also synthesize vitamins like biotin and folate, and facilitate absorption of dietary minerals, including magnesium, calcium, and iron.[6][22] Methanobrevibacter smithii is unique because it is not a species of bacteria, but rather a member of domain Archaea, and is the most abundant methane-producing archaeal species in the human gastrointestinal microbiota.[72]

Gut microbiota also serve as a source of vitamins K and B12, which are not produced by the body or produced in little amount.[73][74]

Cellulose degradation

[edit]

Bacteria that degrade cellulose (such as Ruminococcus) are prevalent among great apes, ancient human societies, hunter-gatherer communities, and even modern rural populations. However, they are rare in industrialized societies. Human-associated strains have acquired genes that can degrade specific plant fibers such as maize, rice, and wheat. Bacterial strains found in primates can also degrade chitin, a polymer abundant in insects, which are part of the diet of many nonhuman primates. The decline of these bacteria in the human gut were likely influenced by the shift toward western lifestyles.[75]

Pharmacomicrobiomics

[edit]

The human metagenome (i.e., the genetic composition of an individual and all microorganisms that reside on or within the individual's body) varies considerably between individuals.[76][77] Since the total number of microbial cells in the human body (over 100 trillion) greatly outnumbers Homo sapiens cells (tens of trillions),[note 1][76][78] there is considerable potential for interactions between drugs and an individual's microbiome, including: drugs altering the composition of the human microbiome, drug metabolism by microbial enzymes modifying the drug's pharmacokinetic profile, and microbial drug metabolism affecting a drug's clinical efficacy and toxicity profile.[76][77][79]

Apart from carbohydrates, gut microbiota can also metabolize other xenobiotics such as drugs, phytochemicals, and food toxicants. More than 30 drugs have been shown to be metabolized by gut microbiota.[80] The microbial metabolism of drugs can sometimes inactivate the drug.[81]

Contribution to drug metabolism
[edit]

The gut microbiota is an enriched community that contains diverse genes with huge biochemical capabilities to modify drugs, especially those taken by mouth.[82] Gut microbiota can affect drug metabolism via direct and indirect mechanisms.[83] The direct mechanism is mediated by the microbial enzymes that can modify the chemical structure of the administered drugs.[84] Conversely, the indirect pathway is mediated by the microbial metabolites which affect the expression of host metabolizing enzymes such as cytochrome P450.[85][83] The effects of the gut microbiota on the pharmacokinetics and bioavailability of the drug have been investigated a few decades ago.[86][87][88] These effects can be varied; it could activate the inactive drugs such as lovastatin,[89] inactivate the active drug such as digoxin[90] or induce drug toxicity as in irinotecan.[91] Since then, the impacts of the gut microbiota on the pharmacokinetics of many drugs were heavily studied.[92][82]

The human gut microbiota plays a crucial role in modulating the effect of the administered drugs on the human. Directly, gut microbiota can synthesize and release a series of enzymes with the capability to metabolize drugs such as microbial biotransformation of L-dopa by decarboxylase and dehydroxylase enzymes.[84] On the contrary, gut microbiota may also alter the metabolism of the drugs by modulating the host drug metabolism. This mechanism can be mediated by microbial metabolites or by modifying host metabolites which in turn change the expression of host metabolizing enzymes.[85]

A large number of studies have demonstrated the metabolism of over 50 drugs by the gut microbiota.[92][83] For example, lovastatin (a cholesterol-lowering agent) which is a lactone prodrug is partially activated by the human gut microbiota forming active acid hydroxylated metabolites.[89] Conversely, digoxin (a drug used to treat Congestive Heart Failure) is inactivated by a member of the gut microbiota (i.e. Eggerthella lanta).[93] Eggerthella lanta has a cytochrome-encoding operon up-regulated by digoxin and associated with digoxin-inactivation.[93] Gut microbiota can also modulate the efficacy and toxicity of chemotherapeutic agents such as irinotecan.[94] This effect is derived from the microbiome-encoded β-glucuronidase enzymes which recover the active form of the irinotecan causing gastrointestinal toxicity.[95]

Secondary metabolites
[edit]

This microbial community in the gut has a huge biochemical capability to produce distinct secondary metabolites that are sometimes produced from the metabolic conversion of dietary foods such as fibers, endogenous biological compounds such as indole or bile acids.[96][97][98] Microbial metabolites especially short chain fatty acids (SCFAs) and secondary bile acids (BAs) play important roles for the human in health and disease states.[99][100][101]

One of the most important bacterial metabolites produced by the gut microbiota is secondary bile acids (BAs).[98] These metabolites are produced by the bacterial biotransformation of the primary bile acids such as cholic acid (CA) and chenodeoxycholic acid (CDCA) into secondary bile acids (BAs) lithocholic acid (LCA) and deoxy cholic acid (DCA) respectively.[102] Primary bile acids which are synthesized by hepatocytes and stored in the gall bladder possess hydrophobic characters. These metabolites are subsequently metabolized by the gut microbiota into secondary metabolites with increased hydrophobicity.[102] Bile salt hydrolases (BSH) which are conserved across gut microbiota phyla such as Bacteroides, Firmicutes, and Actinobacteria responsible for the first step of secondary bile acids metabolism.[102] Secondary bile acids (BAs) such as DCA and LCA have been demonstrated to inhibit both Clostridioides difficile germination and outgrowth.[101]

Dysbiosis

[edit]

The gut microbiota is important for maintaining homeostasis in the intestine. Development of intestinal cancer is associated with an imbalance in the natural microflora (dysbiosis).[103] The secondary bile acid deoxycholic acid is associated with alterations of the microbial community that lead to increased intestinal carcinogenesis.[103] Increased exposure of the colon to secondary bile acids resulting from dysbiosis can cause DNA damage, and such damage can produce carcinogenic mutations in cells of the colon.[104] The high density of bacteria in the colon (about 1012 per ml.) that are subject to dysbiosis compared to the relatively low density in the small intestine (about 102 per ml.) may account for the greater than 10-fold higher incidence of cancer in the colon compared to the small intestine.[104]

Gut–brain axis

[edit]

The gut microbiota contributes to digestion and immune modulation, as it plays a role in the gut-brain axis, where microbial metabolites such as short-chain fatty acids and neurotransmitters influence brain function and behavior. The gut–brain axis is the biochemical signaling that takes place between the gastrointestinal tract and the central nervous system.[59] That term has been expanded to include the role of the gut flora in the interplay; the term "microbiome––brain axis" is sometimes used to describe paradigms explicitly including the gut flora.[59][105][106] Broadly defined, the gut-brain axis includes the central nervous system, neuroendocrine and neuroimmune systems including the hypothalamic–pituitary–adrenal axis (HPA axis), sympathetic and parasympathetic arms of the autonomic nervous system including the enteric nervous system, the vagus nerve, and the gut microbiota.[59][106]

A 2016 systematic review of preclinical studies and small human trials conducted with certain commercially available strains of probiotic bacteria found that Bifidobacterium and Lactobacillus genera (B. longum, B. breve, B. infantis, L. helveticus, L. rhamnosus, L. plantarum, and L. casei), were of interest for certain central nervous system disorders.[16]

Alterations in microbiota balance

[edit]

Effects of antibiotic use

[edit]

Altering the numbers of gut bacteria, for example by taking broad-spectrum antibiotics, may affect the host's health and ability to digest food.[107] Antibiotics can cause antibiotic-associated diarrhea by irritating the bowel directly, changing the levels of microbiota, or allowing pathogenic bacteria to grow.[7] Another harmful effect of antibiotics is the increase in numbers of antibiotic-resistant bacteria found after their use, which, when they invade the host, cause illnesses that are difficult to treat with antibiotics.[107]

Changing the numbers and species of gut microbiota can reduce the body's ability to ferment carbohydrates and metabolize bile acids and may cause diarrhea. Carbohydrates that are not broken down may absorb too much water and cause runny stools, or lack of SCFAs produced by gut microbiota could cause diarrhea.[7]

A reduction in levels of native bacterial species also disrupts their ability to inhibit the growth of harmful species such as C. difficile and Salmonella Kedougou, and these species can get out of hand, though their overgrowth may be incidental and not be the true cause of diarrhea.[6][7][107] Emerging treatment protocols for C. difficile infections involve fecal microbiota transplantation of donor feces (see Fecal transplant).[108] Initial reports of treatment describe success rates of 90%, with few side effects. Efficacy is speculated to result from restoring bacterial balances of bacteroides and firmicutes classes of bacteria.[109]

The composition of the gut microbiome also changes in severe illnesses, due not only to antibiotic use but also to such factors as ischemia of the gut, failure to eat, and immune compromise. Negative effects from this have led to interest in selective digestive tract decontamination, a treatment to kill only pathogenic bacteria and allow the re-establishment of healthy ones.[110]

Antibiotics alter the population of the microbiota in the gastrointestinal tract, and this may change the intra-community metabolic interactions, modify caloric intake by using carbohydrates, and globally affect host metabolic, hormonal, and immune homeostasis.[111]

There is reasonable evidence that taking probiotics containing Lactobacillus species may help prevent antibiotic-associated diarrhea and that taking probiotics with Saccharomyces (e.g., Saccharomyces boulardii ) may help to prevent Clostridioides difficile infection following systemic antibiotic treatment.[112]

Pregnancy

[edit]

The gut microbiota of a woman changes as pregnancy advances, with the changes similar to those seen in metabolic syndromes such as diabetes. The change in gut microbiota causes no ill effects. The newborn's gut microbiota resemble the mother's first-trimester samples. The diversity of the microbiome decreases from the first to third trimester, as the numbers of certain species go up.[113][114]

Probiotics, prebiotics, synbiotics, and pharmabiotics

[edit]

Probiotics contain live microorganisms. When consumed, they are believed to provide health benefits by altering the microbiome composition.[115][116][117] Current research explores using probiotics as a way to restore the microbial balance of the intestine by stimulating the immune system and inhibiting pro-inflammatory cytokines.[115]

With regard to gut microbiota, prebiotics are typically non-digestible, fiber compounds that pass undigested through the upper part of the gastrointestinal tract and stimulate the growth or activity of advantageous gut flora by acting as substrate for them.[39][118]

Synbiotics refers to food ingredients or dietary supplements combining probiotics and prebiotics in a form of synergism.[119]

The term "pharmabiotics" is used in various ways, to mean: pharmaceutical formulations (standardized manufacturing that can obtain regulatory approval as a drug) of probiotics, prebiotics, or synbiotics;[120] probiotics that have been genetically engineered or otherwise optimized for best performance (shelf life, survival in the digestive tract, etc.);[121] and the natural products of gut flora metabolism (vitamins, etc.).[122]

There is some evidence that treatment with some probiotic strains of bacteria may be effective in treatment of irritable bowel syndrome, inflammatory bowel disease, and abdominal bloating.[123][124][125][126] Those organisms most likely to result in a decrease of symptoms have included:

Research

[edit]

Tests for whether non-antibiotic drugs may impact human gut-associated bacteria were performed by in vitro analysis on more than 1000 marketed drugs against 40 gut bacterial strains, demonstrating that 24% of the drugs inhibited the growth of at least one of the bacterial strains.[127]

Role in disease

[edit]

Bacteria in the digestive tract can contribute to and be affected by disease in various ways. The presence or overabundance of some kinds of bacteria may contribute to inflammatory disorders such as inflammatory bowel disease.[6] Additionally, metabolites from certain members of the gut flora may influence host signalling pathways, contributing to disorders such as obesity and colon cancer.[6] Some gut bacteria may also cause infections and sepsis, for example when they are allowed to pass from the gut into the rest of the body.[6]

Ulcers

[edit]

Helicobacter pylori infection can initiate formation of stomach ulcers when the bacteria penetrate the stomach epithelial lining, then causing an inflammatory phagocytotic response.[128] In turn, the inflammation damages parietal cells which release excessive hydrochloric acid into the stomach and produce less of the protective mucus.[129] Injury to the stomach lining, leading to ulcers, develops when gastric acid overwhelms the defensive properties of cells and inhibits endogenous prostaglandin synthesis, reduces mucus and bicarbonate secretion, reduces mucosal blood flow, and lowers resistance to injury.[129] Reduced protective properties of the stomach lining increase vulnerability to further injury and ulcer formation by stomach acid, pepsin, and bile salts.[128][129]

Bowel perforation

[edit]

Normally-commensal bacteria can harm the host if they extrude from the intestinal tract.[12][13] Translocation, which occurs when bacteria leave the gut through its mucosal lining, can occur in a number of different diseases.[13] If the gut is perforated, bacteria invade the interstitium, causing a potentially fatal infection.[5]: 715 

Inflammatory bowel diseases

[edit]

The two main types of inflammatory bowel diseases, Crohn's disease and ulcerative colitis, are chronic inflammatory disorders of the gut; the causes of these diseases are unknown and issues with the gut flora and its relationship with the host have been implicated in these conditions.[15][130][131][132] Additionally, it appears that interactions of gut flora with the gut–brain axis have a role in IBD, with physiological stress mediated through the hypothalamic–pituitary–adrenal axis driving changes to intestinal epithelium and the gut flora in turn releasing factors and metabolites that trigger signaling in the enteric nervous system and the vagus nerve.[4]

The diversity of gut flora appears to be significantly diminished in people with inflammatory bowel diseases compared to healthy people; additionally, in people with ulcerative colitis, Proteobacteria and Actinobacteria appear to dominate; in people with Crohn's, Enterococcus faecium and several Proteobacteria appear to be over-represented.[4]

There is reasonable evidence that correcting gut flora imbalances by taking probiotics with Lactobacilli and Bifidobacteria can reduce visceral pain and gut inflammation in IBD.[112]

Irritable bowel syndrome

[edit]

Irritable bowel syndrome is a result of stress and chronic activation of the HPA axis; its symptoms include abdominal pain, changes in bowel movements, and an increase in proinflammatory cytokines. Overall, studies have found that the luminal and mucosal microbiota are changed in irritable bowel syndrome individuals, and these changes can relate to the type of irritation such as diarrhea or constipation. Also, there is a decrease in the diversity of the microbiome with low levels of fecal Lactobacilli and Bifidobacteria, high levels of facultative anaerobic bacteria such as Escherichia coli, and increased ratios of Firmicutes: Bacteroidetes.[106]

Asthma

[edit]

With asthma, two hypotheses have been posed to explain its rising prevalence in the developed world. The hygiene hypothesis posits that children in the developed world are not exposed to enough microbes and thus may contain lower prevalence of specific bacterial taxa that play protective roles.[133] The second hypothesis focuses on the Western pattern diet, which lacks whole grains and fiber and has an overabundance of simple sugars.[15] Both hypotheses converge on the role of short-chain fatty acids (SCFAs) in immunomodulation. These bacterial fermentation metabolites are involved in immune signalling that prevents the triggering of asthma and lower SCFA levels are associated with the disease.[133][134] Lacking protective genera such as Lachnospira, Veillonella, Rothia and Faecalibacterium has been linked to reduced SCFA levels.[133] Further, SCFAs are the product of bacterial fermentation of fiber, which is low in the Western pattern diet.[15][134] SCFAs offer a link between gut flora and immune disorders, and as of 2016, this was an active area of research.[15] Similar hypotheses have also been posited for the rise of food and other allergies.[135]

Diabetes mellitus type 1

[edit]

The connection between the gut microbiota and diabetes mellitus type 1 has also been linked to SCFAs, such as butyrate and acetate. Diets yielding butyrate and acetate from bacterial fermentation show increased Treg expression.[136] Treg cells downregulate effector T cells, which in turn reduces the inflammatory response in the gut.[137] Butyrate is an energy source for colon cells. butyrate-yielding diets thus decrease gut permeability by providing sufficient energy for the formation of tight junctions.[138] Additionally, butyrate has also been shown to decrease insulin resistance, suggesting gut communities low in butyrate-producing microbes may increase chances of acquiring diabetes mellitus type 2.[139] Butyrate-yielding diets may also have potential colorectal cancer suppression effects.[138]

Type 2 diabetes

[edit]

The gut microbiota are very important for the host health because they play role in degradation of non-digestible polysaccharides (fermentation of resistant starch, oligosaccharides, inulin) strengthening gut integrity or shaping the intestinal epithelium, harvesting energy, protecting against pathogens, and regulating host immunity.[140][141]

Several studies showed that the gut bacterial composition in diabetic patients became altered with increased levels of Lactobacillus gasseri, Streptococcus mutans and Clostridiales members, with decrease in butyrate-producing bacteria such as Roseburia intestinalis and Faecalibacterium prausnitzii.[142][143] This alteration is due to many factors such as antibiotic abuse, diet, and age.

The decrease in butyrate production is associated with defects in intestinal permeability, which could lead to endotoxemia, which is the increased level of circulating Lipopolysaccharides from gram negative bacterial cells wall. It is found that endotoxemia has association with development of insulin resistance.[142]

In addition that butyrate production affects serotonin level.[142] Elevated serotonin level has contribution in obesity, which is known to be a risk factor for development of diabetes.

Cancer

[edit]

The human gut microbial composition is modulated by dietary bile acids.[144][145] There appears to be a metabolic link between cancer associated gut microbes and a fat- and meat rich diet.[146] In rodents, elevated levels of bile acids produced by the gut microbiota in response to a high fat diet are associated with an increased the risk of colorectal cancer.[145] The secondary bile acid deoxycholic acid, produced from the primary bile acid cholic acid by the gut microbiota, is elevated in the colonic contents of humans in response to a high fat diet.[144][145] In populations that have a high incidence of colorectal cancer fecal concentrations of bile acids, particularly deoxycholic acid produced by the action of gut microbiota, are higher.[144][145]

Development and antibiotics

[edit]

The colonization of the human gut microbiota may start already before birth.[147] There are multiple factors in the environment that affects the development of the microbiota with birthmode being one of the most impactful.[148]

Another factor that has been observed to cause huge changes in the gut microbiota, particularly in children, is the use of antibiotics, associating with health issues such as higher BMI,[149][150] and further an increased risk towards metabolic diseases such as obesity.[151] In infants it was observed that amoxicillin and macrolides cause significant shifts in the gut microbiota characterized by a change in the bacterial classes Bifidobacteria, Enterobacteria and Clostridia.[152] A single course of antibiotics in adults causes changes in both the bacterial and fungal microbiota, with even more persistent changes in the fungal communities.[153] The bacteria and fungi live together in the gut and there is most likely a competition for nutrient sources present.[154][155] Seelbinder et al. found that commensal bacteria in the gut regulate the growth and pathogenicity of Candida albicans by their metabolites, particularly by propionate, acetic acid and 5-dodecenoate.[153] Candida has previously been associated with IBD[156] and further it has been observed to be increased in non-responders to a biological drug, infliximab, given to IBD patients with severe IBD.[157] Propionate and acetic acid are both short-chain fatty acids (SCFAs) that have been observed to be beneficial to gut microbiota health.[158][159][160] When antibiotics affect the growth of bacteria in the gut, there might be an overgrowth of certain fungi, which might be pathogenic when not regulated.[153]

Blood–brain barrier dysfunction

[edit]

The gut microbiome regulates the function of the blood–brain barrier (BBB) throughout life, at least partially due to microbial metabolites.[161] The BBB is a selectively permeable membrane that tightly regulates the transfer of substances between the circulation and the brain parenchyma.[162] During development, germ-free mice exhibit increased BBB permeability from embryonic stages through adulthood with reduced tight junction proteins, while colonization with mature microbiota restores barrier function through SCFAs like butyrate.[163] This developmental impact persists, as mice with gut microbiota associated with preterm birth show early-life BBB hyperpermeability and cognitive deficits, whereas those with microbiota associated with full-term birth maintain an intact BBB.[164] During aging, altered microbiota composition with increased Firmicutes/Bacteroidetes ratio correlates with compromised BBB function, reduced P-glycoprotein activity, and cognitive impairment.[165] These effects may be mediated by microbial metabolites including SCFAs that enhance barrier integrity and methylamines, where trimethylamine N-oxide protects BBB function while its precursor trimethylamine disrupts it.[166][167][168][169]

Obesity and metabolic syndrome

[edit]

The gut flora have been implicated in obesity and metabolic syndrome due to a key role in the digestive process; the Western pattern diet appears to drive and maintain changes in the gut flora that in turn change how much energy is derived from food and how that energy is used.[132][170] One aspect of a healthy diet that is often lacking in the Western-pattern diet is fiber and other complex carbohydrates that a healthy gut flora require flourishing; changes to gut flora in response to a Western-pattern diet appear to increase the amount of energy generated by the gut flora which may contribute to obesity and metabolic syndrome.[112] There is also evidence that microbiota influence eating behaviours based on the preferences of the microbiota, which can lead to the host consuming more food eventually resulting in obesity. It has generally been observed that with higher gut microbiome diversity, the microbiota will spend energy and resources on competing with other microbiota and less on manipulating the host. The opposite is seen with lower gut microbiome diversity, and these microbiotas may work together to create host food cravings.[55]

Additionally, the liver plays a dominant role in blood glucose homeostasis by maintaining a balance between the uptake and storage of glucose through the metabolic pathways of glycogenesis and gluconeogenesis. Intestinal lipids regulate glucose homeostasis involving a gut–brain–liver axis. The direct administration of lipids into the upper intestine increases the long chain fatty acyl-coenzyme A (LCFA-CoA) levels in the upper intestines and suppresses glucose production even under subdiaphragmatic vagotomy or gut vagal deafferentation. This interrupts the neural connection between the brain and the gut and blocks the upper intestinal lipids' ability to inhibit glucose production. The gut–brain–liver axis and gut microbiota composition can regulate the glucose homeostasis in the liver and provide potential therapeutic methods to treat obesity and diabetes.[171]

Just as gut flora can function in a feedback loop that can drive the development of obesity, there is evidence that restricting intake of calories (i.e., dieting) can drive changes to the composition of the gut flora.[132]

Other animals

[edit]

The composition of the human gut microbiome is similar to that of the other great apes. However, humans' gut biota has decreased in diversity and changed in composition since our evolutionary split from Pan.[172] Humans display increases in Bacteroidetes, a bacterial phylum associated with diets high in animal protein and fat, and decreases in Methanobrevibacter and Fibrobacter, groups that ferment complex plant polysaccharides.[172] These changes are the result of the combined dietary, genetic, and cultural changes humans have undergone since evolutionary divergence from Pan (chimpanzees and bonobos).[citation needed]

In addition to humans and vertebrates, some insects also have complex and diverse gut microbiota that play key nutritional roles.[2] Microbial communities associated with termites can constitute a majority of the weight of the individuals and perform important roles in the digestion of lignocellulose and nitrogen fixation.[173] It is known that the disruption of gut microbiota of termites using agents like antibiotics[174] or boric acid[175] (a common agent used in preventative treatment) causes severe damage to digestive function and leads to the rise of opportunistic pathogens.[142] These communities are host-specific, and closely related insect species share comparable similarities in gut microbiota composition.[176][177] In cockroaches, gut microbiota have been shown to assemble in a deterministic fashion, irrespective of the inoculum;[178] the reason for this host-specific assembly remains unclear. Bacterial communities associated with insects like termites and cockroaches are determined by a combination of forces, primarily diet, but there is some indication that host phylogeny may also be playing a role in the selection of lineages.[176][177]

For more than 51 years it has been known that the administration of low doses of antibacterial agents promotes the growth of farm animals to increase weight gain.[111]

In a study carried out on mice the ratio of Firmicutes and Lachnospiraceae was significantly elevated in animals treated with subtherapeutic doses of different antibiotics. By analyzing the caloric content of faeces and the concentration of small chain fatty acids (SCFAs) in the GI tract, it was concluded that the changes in the composition of microbiota lead to an increased capacity to extract calories from otherwise indigestible constituents, and to an increased production of SCFAs. These findings provide evidence that antibiotics perturb not only the composition of the GI microbiome but also its metabolic capabilities, specifically with respect to SCFAs.[111]

See also

[edit]

Notes

[edit]

References

[edit]

Further reading

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
The gut microbiota refers to the diverse community of microorganisms—including trillions of , , fungi, viruses, and —that colonize the gastrointestinal (GI) tract and interact symbiotically with the host to influence digestion, metabolism, immunity, and overall health. The study of the gut microbiota dates back to the , when first observed microbes using early microscopes, followed by 19th-century advancements by and Élie Metchnikoff on microbial roles in and immunity, and a surge in the driven by metagenomic sequencing technologies that revealed its vast complexity. This ecosystem contains an estimated 10^{13} to 10^{14} microbial cells, which slightly outnumbers cells (approximately 1.3:1 ratio for bacterial cells), and encodes a collective genome orders of magnitude larger than the , enabling functions essential for host physiology. The composition of the gut microbiota varies along the GI tract, with microbial density increasing dramatically from proximal to distal regions: the harbors around 10^1 to 10^3 cells per gram of content, the ranges from 10^3 to 10^4 in proximal areas to up to 10^8 in the distal , while the colon supports the highest density (10^{11} to 10^{12} cells per gram), dominated by anaerobic . constitute the majority, primarily from the phyla Firmicutes and Bacteroidetes (accounting for over 90% in many individuals), alongside Actinobacteria, Proteobacteria, Fusobacteria, and Verrucomicrobia; like Methanobrevibacter, fungi such as Candida, and viruses including bacteriophages also contribute to this dynamic community. Diversity is highest in the colon, where factors like pH, nutrient availability, oxygen levels, and transit time shape microbial distribution and function. The gut microbiota develops rapidly from birth, initially shaped by delivery mode (vaginal vs. cesarean), , and environmental exposures, stabilizing into an adult-like profile by around age 3 with increased richness and stability. Key functions include fermenting undigested dietary fibers into (SCFAs) like butyrate for energy and gut barrier integrity, synthesizing vitamins (e.g., B and K), metabolizing acids and xenobiotics, and modulating the by training T cells and producing anti-inflammatory compounds to prevent invasion. Disruptions in microbiota composition () are linked to diseases such as , , , and neurological disorders, underscoring its role in maintaining host .

Introduction

Definition and Scope

The gut microbiota refers to the diverse community of microorganisms, including primarily but also , fungi, viruses, and other eukaryotes, that inhabit the human . This microbial consists of trillions of cells, estimated at 10^13 to 10^14 in total, comparable in number to human cells (ratio of approximately 1.3:1, with about 38 trillion bacterial cells and 30 trillion human cells as of 2016). In healthy individuals, these microorganisms exist in a symbiotic relationship with the host, contributing to essential functions such as while maintaining ecological balance; disruptions in this , known as , can alter community structure and function. The scope of the gut microbiota encompasses both resident and transient components, with resident microbes forming a stable, long-term population adapted to the host environment, while transient ones originate from external sources like diet or the surroundings and are typically cleared without establishing permanence. The serves as the primary habitat, but microbial density and diversity vary markedly by region: the acidic (pH 1.5–3.5) supports only low, mostly transient populations (10^3 to 10^6 cells per gram of contents), whereas the intestines—particularly the colon—host the vast majority of resident microbes at densities exceeding 10^11 cells per gram. This distinction underscores the intestines as the core site of microbiota activity in humans. Diversity within the gut microbiota is quantified using ecological metrics, including , which measures and evenness within an individual sample, and , which assesses compositional differences between samples or individuals. These indices highlight the microbiota's complexity, with healthy adult profiles typically exhibiting high (hundreds to thousands of species) that supports resilience against perturbations. Overall, the human gut microbiota's scale and variability emphasize its centrality to individual , though specifics like age- or geography-related shifts influence its profile.

Historical Development

The scientific understanding of gut microbiota began in the late 17th century with Antonie van Leeuwenhoek's pioneering use of microscopy to observe microorganisms, including bacteria in his own stool and saliva samples in 1681 and 1683, marking the first documented visualization of intestinal microbes. In the 19th century, Louis Pasteur advanced the field by identifying bacteria and yeasts responsible for lactic acid fermentation in milk, laying foundational knowledge on microbial processes in the gut without directly linking them to human health benefits. Élie Metchnikoff, building on Pasteur's work at the Pasteur Institute, extended these observations in the early 1900s by hypothesizing that consuming fermented dairy products containing lactobacilli could modulate the intestinal microbiome to promote health and extend lifespan, an idea inspired by the longevity of Bulgarian peasants who regularly ingested yogurt. Metchnikoff's 1908 Nobel Prize in Physiology or Medicine, awarded jointly with for work on immunity, indirectly bolstered his probiotic hypothesis, as his research emphasized the role of beneficial gut bacteria in countering harmful ones to delay . Progress stalled until the mid-20th century, when advancements in anaerobic cultivation techniques in the and , including the use of anaerobic jars and glove boxes, enabled the isolation of obligate anaerobes that dominate the gut, revealing a far more complex and diverse microbial ecosystem than previously appreciated through aerobic cultures alone. The field accelerated in the 21st century with the launch of the Human Microbiome Project by the in 2007, which aimed to characterize the microbial communities across the human body, including the gut, through metagenomic sequencing and generated reference genomes for over 1,000 microbial strains. A landmark 2011 study by the MetaHIT consortium, led by Peer Bork, introduced the concept of enterotypes—three distinct, stable clusters of gut microbiota composition based on bacterial genera dominance, providing a framework for understanding microbial community organization independent of host geography. In the 2010s, randomized controlled trials demonstrated the efficacy of fecal microbiota transplantation (FMT) for treating recurrent infections, with success rates exceeding 90% in duodenal infusion studies, reviving interest in microbial transfer as a therapeutic strategy. Post-2020 developments have integrated multi-omics approaches, combining for microbial with to map host-microbe interactions, enabling deeper insights into dynamic gut ecosystem responses to diet and disease. Concurrently, AI-driven predictive modeling has emerged in the to simulate dynamics, using on longitudinal sets to forecast community stability and responses to perturbations, as seen in frameworks that integrate multi-omics for personalized health predictions.

Composition and Diversity

Bacterial Dominance

The gut microbiota is predominantly bacterial, with the phyla Firmicutes and Bacteroidetes comprising approximately 90% of the microbial community in healthy adults. Firmicutes include key genera such as and , while Bacteroidetes are represented by genera like and . Minor phyla, including Actinobacteria (e.g., ), Proteobacteria (e.g., ), and Verrucomicrobia (e.g., ), constitute the remaining fraction, often less than 10% of the total abundance. Bacterial composition varies significantly across gastrointestinal tract regions, influenced by local environmental conditions such as , oxygen levels, and nutrient availability. In the , microbial diversity is low due to acidic conditions, with dominant taxa including (when present) and . The features moderate diversity, primarily inhabited by facultative anaerobes like and members of , reflecting faster transit and exposure. In contrast, the harbors the highest bacterial density and diversity, with 500–1000 species dominated by strict anaerobes such as , , and other Firmicutes and Bacteroidetes members. Human gut bacterial communities cluster into three distinct enterotypes, characterized by dominance of (enterotype 1), (enterotype 2), or (enterotype 3). These enterotypes correlate with long-term dietary patterns, such as higher protein and fat intake favoring Bacteroides-dominated profiles, while fiber-rich diets promote Prevotella abundance, influencing metabolic functions and health outcomes. Taxonomic profiling of the gut microbiota relies heavily on 16S rRNA gene sequencing, which targets conserved genes to classify at the phylum, , and levels. This approach has identified a core of shared taxa present in most healthy individuals, including prausnitzii (a prominent Firmicutes comprising up to 15% of fecal ), which contributes to community stability.

Eukaryotic and Viral Components

The gut mycobiome, comprising the fungal component of the microbiota, consists of over 66 genera and 184 species, representing approximately 0.1% of the total microbial community in healthy individuals. Dominant genera include Candida and , with being particularly prevalent as a commensal that can form biofilms in the intestinal environment. These fungi contribute to immune by training mucosal immunity, where their presence promotes balanced inflammatory responses and tolerance in the gut epithelium.30243-2) However, in states of , such as during use or immune deficiencies, fungal overgrowth—particularly of Candida species—can occur, leading to and increased susceptibility to opportunistic infections. The gut virome encompasses both bacteriophages and eukaryotic viruses, with bacteriophages vastly outnumbering other components at an estimated 10^{15} particles in the human gastrointestinal tract. Bacteriophages, primarily temperate phages that integrate into bacterial genomes via lysogeny, dominate the virome and exhibit dynamics between lysogenic persistence and lytic cycles that regulate bacterial populations.30456-X) Eukaryotic viruses, such as enteroviruses, constitute a minor fraction and are often associated with transient infections rather than stable residency.00212-8) These viral elements influence microbial through selective pressure on bacterial hosts, maintaining diversity via co-evolutionary arms races where phages adapt to bacterial defenses like systems.00057-X) Archaea in the gut, primarily methanogenic species, account for about 1-2% of the total and play a key role in by consuming H_2 produced by bacterial , thereby reducing gas accumulation and influencing harvest from diet. The dominant archaeon, , utilizes H_2 and CO_2 to produce , which is expelled and helps maintain anaerobic conditions favorable for other microbes. This metabolic activity links archaea to host physiology, including modulation of short-chain fatty acid production indirectly through bacterial interactions. Interactions among these components shape the gut , with notable antagonism between fungi and bacteria exemplified by biofilms, which can be disrupted or invaded by anaerobic bacteria like species, altering fungal persistence and promoting community stability.01070-7) Similarly, phage-bacteria co-evolution drives strain-level diversity, as phages target specific bacterial variants, fostering adaptive resistance mechanisms that enhance overall resilience. These interkingdom dynamics underscore the virome and mycobiome's regulatory influence despite their lower abundance compared to bacteria.

Factors Shaping Diversity

Host play a pivotal role in shaping the composition and diversity of the gut through specific genetic variants that influence microbial adhesion and susceptibility. For instance, polymorphisms in the (HLA) genes, particularly in the region, have been associated with distinct profiles, where individuals sharing HLA variants exhibit similar microbial communities, potentially modulating immune responses to microbial antigens. Similarly, the fucosyltransferase 2 (FUT2) gene regulates in the , with non-secretor alleles leading to reduced fucosylation that impairs adhesion of beneficial bacteria like species, thereby altering overall microbial diversity and increasing susceptibility to pathogens. Initial colonization during birth and early infancy establishes foundational diversity patterns that persist into adulthood. Vaginally delivered infants acquire a microbiota enriched in species from maternal vaginal and fecal sources, fostering early microbial diversity, whereas cesarean section delivery results in initial seeding by skin-associated bacteria such as and , which delays the establishment of a mature gut community. further promotes diversity by providing human milk oligosaccharides that selectively nourish and other beneficial taxa, enhancing colonization resistance and microbial maturation in the first months of life. Spatial gradients within the create distinct ecological niches that drive microbial diversity through physicochemical selective pressures. Oxygen levels decrease progressively from the oxygen-rich to the anaerobic colon, favoring facultative anaerobes proximally and obligate anaerobes distally, while rises from acidic conditions in the proximal gut (around 5-6) to near-neutral in the colon (6.5-7), influencing microbial metabolic capabilities. acids, concentrated in the and proximal colon, select for specialized deconjugating and dehydroxylating bacteria, such as species (e.g., Clostridium scindens), which transform primary bile acids into secondary forms, thereby shaping community structure and preventing overgrowth of less adapted taxa. The gut microbiota exhibits inherent stability characterized by resilience to perturbations and the distinction between core and variable taxa. taxa, such as and , are consistently present across healthy individuals and contribute to functional stability, while variable taxa respond to niche-specific conditions, allowing adaptability without compromising overall community integrity. This resilience enables rapid recovery from transient disruptions, maintaining diversity through mechanisms like competitive exclusion and metabolic cross-feeding among taxa.

Influences on Gut Microbiota

The gut microbiota begins its development in a near-sterile state in the , with initial occurring rapidly during and immediately after birth through exposure to maternal vaginal, , and environmental microbes. In breastfed infants, this early is predominantly composed of species, which can constitute up to 90% of the fecal microbiota in the first six months of life, facilitated by human milk oligosaccharides that selectively promote their growth. This -dominated profile supports immune maturation and pathogen resistance during this vulnerable period. As infants transition to childhood, the gut microbiota undergoes significant diversification, approaching an adult-like composition by around three years of age. This shift is marked by a decrease in Actinobacteria (including ) and an increase in Firmicutes and Bacteroidetes phyla, particularly during when solid foods are introduced, which broadens microbial metabolic capabilities. Dietary changes during this phase play a key role in stabilizing this diversification, though specifics are influenced by individual exposures. By , the microbiota generally stabilizes, reflecting a mature ecosystem adapted to the host's nutritional and physiological needs. In healthy adults, typically from ages 20 to 50, the gut microbiota exhibits relative stability, with core taxa such as Firmicutes and Bacteroidetes dominating and comprising over 90% of the community, subject only to minor fluctuations from transient factors like diet or . This plateau supports consistent metabolic and immune functions throughout prime adulthood. During aging, particularly after age 60, the gut microbiota experiences a decline in overall diversity, with reduced metrics such as lower Shannon index values compared to younger adults. This is accompanied by shifts in composition, including an enrichment of Proteobacteria and pathobionts like . These alterations are associated with increased frailty markers, such as reduced physical function and , though direct causation remains unestablished.

Environmental and Geographic Variations

The composition of the human gut microbiota varies substantially across geographic regions, primarily driven by local dietary patterns and environmental factors. Populations in Western countries, where diets are typically high in animal fats and proteins, exhibit a predominance of the Bacteroides enterotype, characterized by higher abundances of species that efficiently metabolize such nutrients. In contrast, non-Western and rural populations consuming high-fiber, plant-based diets—common in agrarian societies—show enrichment of the Prevotella enterotype, with species adept at degrading complex carbohydrates from fibers and starches. These enterotype differences reflect adaptations to regionally available resources and have been consistently observed in large-scale metagenomic studies spanning diverse global cohorts. Climate and altitude further modulate these geographic patterns, influencing both diversity and functional profiles of the . Gut microbial diversity tends to be higher in tropical zones compared to temperate regions, with a global revealing an increase in (e.g., Shannon index) toward lower latitudes, peaking at intermediate tropical latitudes. This pattern correlates with elevated abundances of Bacteroidetes in warmer climates, potentially aiding host adaptation to fiber-rich tropical diets, while Proteobacteria decrease from high to low latitudes. At higher altitudes, hypobaric hypoxia disrupts microbial communities, generally reducing overall diversity (correlation R = -0.047, P < 0.001 globally), though trends vary by continent; for example, genera like increase with altitude, while and Blautia decline, possibly due to oxygen scarcity affecting pathways. Malnourishment, often linked to resource-scarce environments in developing regions, profoundly alters gut microbiota profiles and exacerbates geographic disparities. Undernourished children, particularly those with —a severe protein-energy malnutrition syndrome prevalent in parts of —display significantly reduced microbial diversity and an immature community structure compared to healthy peers, with lower abundances of beneficial short-chain fatty acid producers. This correlates with and impaired nutrient absorption, as evidenced in longitudinal studies from showing persistent microbiota immaturity even after nutritional rehabilitation. Such patterns highlight how environmental nutrient limitations in specific geographies impair microbiota development. Urbanization introduces additional environmental gradients within geographic contexts, typically leading to lower gut microbiota diversity in dwellers versus rural inhabitants. Enhanced , reduced contact with and animals, and homogenized supplies in urban settings diminish exposure to diverse microbes, resulting in sparser communities; for instance, studies across and other regions report decreased and shifts toward opportunistic pathogens in urban populations. This aligns with the , where limited microbial exposures in urban environments may contribute to immune dysregulation, underscoring the role of built environments in shaping microbiota beyond natural geographic divides.

Lifestyle and Dietary Impacts

Dietary habits profoundly influence the composition and function of the gut microbiota. Consumption of fiber-rich diets promotes the growth of short-chain fatty acid (SCFA)-producing bacteria, such as those in the genus , which ferment indigestible carbohydrates into beneficial metabolites like butyrate and that support intestinal health. In contrast, diets high in protein and saturated fats, common in Western patterns, shift the microbial community toward sulfite-reducing species like , which thrives on taurine-conjugated acids derived from animal products and may contribute to inflammation. Socioeconomic status (SES) also modulates gut diversity through interconnected factors including access to nutritious foods and chronic stressors. Individuals in lower SES neighborhoods exhibit reduced alpha-diversity in their colonic , potentially due to poorer dietary quality and heightened , which collectively impair microbial richness. Urban exacerbates these effects, linking low SES environments to higher of multi-drug resistant organisms and diminished microbial stability. Physical activity and stress levels further shape microbial profiles. Regular aerobic exercise enhances the abundance of mucin-degrading bacteria like Akkermansia muciniphila, which strengthens the gut barrier and correlates with improved metabolic outcomes. Conversely, chronic psychological stress depletes beneficial genera such as Lactobacillus, altering microbiota composition and potentially amplifying stress-related disorders via the gut-brain axis. Subtle microbial differences also emerge across racial and ethnic groups, often reflecting ancestral dietary patterns. For instance, individuals of African ancestry tend to harbor higher levels of compared to those of European ancestry, associated with traditional high-fiber, plant-based diets that favor carbohydrate-fermenting bacteria. These variations underscore how heritage-influenced personal dietary choices sustain distinct microbial ecosystems.

Core Functions

Pathogen Defense and Barrier Functions

The gut microbiota plays a crucial role in defense through mechanisms collectively known as colonization resistance, which prevents the establishment and proliferation of harmful microbes in the intestinal tract. This protection arises from direct antagonism by commensal bacteria, which occupy ecological niches and limit access to essential resources. By maintaining a stable microbial community, the gut microbiota forms a physical and chemical barrier that inhibits invasion and translocation across the . Competitive exclusion is a primary employed by the , where resident outcompete pathogens for and adhesion sites. For instance, species effectively limit serovar Typhimurium colonization by producing propionate, a that restricts the pathogen's access to favorable carbon sources in the gut lumen. This ensures that pathogens like cannot establish niches, thereby reducing their fitness and proliferation. Additionally, commensal occupy spatial niches on mucosal surfaces, preventing pathogens from adhering and invading the host epithelium.30371-8) The microbiota further defends against pathogens through the production of antimicrobial compounds, including and (SCFAs). , such as those secreted by species, are ribosomally synthesized peptides that selectively target and kill closely related by disrupting their cell membranes or essential processes. For example, -derived inhibit the growth of enteric pathogens like without broadly perturbing the commensal community. Complementing this, SCFAs like , propionate, and butyrate—fermentation products of dietary fibers—lower the intestinal pH, creating an acidic environment that inhibits the survival and replication of pH-sensitive pathogens such as and difficile. This pH modulation, particularly in the colon where SCFA concentrations can reach 100-150 mM, enhances the microbiota's overall antimicrobial efficacy. Biofilm formation by microbial consortia strengthens the mucosal barrier, providing a physical shield against pathogen adhesion. Commensal bacteria, including species from the Firmicutes and Bacteroidetes phyla, form multilayered biofilms on the mucus layer, which is composed of mucins secreted by goblet cells. These biofilms fortify the mucus, increasing its thickness and viscosity to block pathogen attachment to epithelial cells; for example, Akkermansia muciniphila promotes mucin production, indirectly enhancing this barrier. Disruptions in fiber intake can thin this mucus layer, allowing pathogens like Citrobacter rodentium to adhere and invade more readily.31396-9) Enteric protection by the microbiota extends to preventing translocation from the gut lumen into the bloodstream, a critical step in systemic infections. Through sustained colonization resistance, commensals maintain epithelial integrity and limit bacterial dissemination; studies in germ-free models show that microbiota-replete hosts exhibit reduced translocation of pathogens like during . This barrier function is compromised in , where reduced microbial diversity permits pathogens to breach the and enter circulation, underscoring the microbiota's role in averting bacteremia.

Immune System Priming

The gut microbiota plays a pivotal role in priming the host by educating immune cells to distinguish between harmless commensals and potential threats, thereby establishing immune in the intestinal mucosa. Through continuous interactions, microbial components and metabolites influence the differentiation and function of various immune cell subsets, fostering tolerance to the microbiota while enabling robust responses to pathogens. This priming process begins early in life and is essential for the maturation of both innate and adaptive immunity, preventing excessive that could lead to or chronic disorders. In tolerance induction, certain members of the Clostridiales order promote the development of regulatory T cells (Tregs), which suppress aberrant immune responses and maintain mucosal tolerance. These bacteria, including clusters IV and XIVa, induce Treg expansion in the by stimulating the production of transforming growth factor-β (TGF-β) from epithelial cells and dendritic cells, leading to expression in Tregs. This mechanism has been shown to prevent in experimental models, where colonization with Clostridia-enriched consortia enhances Treg frequencies and reduces inflammatory T cell responses. For innate immunity, the microbiota provides that activate receptors, such as Toll-like receptors (TLRs), to train innate immune cells for balanced surveillance. (LPS) from serves as a key TLR4 , delivering low-level signals that promote epithelial integrity and maturation without triggering excessive . Additionally, segmented filamentous bacteria (SFB) specifically drive the accumulation of Th17 cells in the by adhering to epithelial cells and inducing serum amyloid A3 (SAA3) production, which activates dendritic cells to promote IL-17 and IL-22 secretion for mucosal protection. Adaptive immune responses are shaped by the through the promotion of secretory (IgA) production, which selectively targets pathobionts—commensal species with pathogenic potential under dysbiotic conditions. Plasma cells in the , guided by microbial cues, generate IgA that coats and limits the invasive growth of these , such as certain , thereby containing them to the lumen. The also modulates function, enhancing their ability to sample antigens and present them to T cells in a tolerogenic manner; for instance, commensal-derived signals upregulate production in dendritic cells, directing IgA class switching in B cells. Early-life colonization by the is critical for maturation, as demonstrated in germ-free models that exhibit profound deficits in immune development. Germ-free mice display reduced lymphoid tissue organization, lower numbers, and impaired responses due to the absence of microbial stimuli, which normally drive the expansion of and T cell subsets. Monocolonization or conventionalization of these models with complex restores immune architecture, underscoring the necessity of timely microbial exposure for establishing lifelong immune competence.

Metabolic Contributions

The gut microbiota plays a pivotal role in host by fermenting indigestible dietary components, such as complex including , which humans lack the enzymes to break down. Bacteria like Bacteroides ovatus produce cellulases that degrade into simpler sugars, enabling further microbial processing. This fermentation primarily occurs in the colon through anaerobic glycolysis pathways, yielding (SCFAs) such as , propionate, and butyrate as major end products. These SCFAs serve as an energy source for colonocytes and contribute to overall host . Beyond fermentation, the microbiota synthesizes essential vitamins that complement host nutrition, particularly B-group vitamins critical for metabolic processes. For instance, contributes to the production of (menaquinone), a cofactor in and , through its biosynthetic pathways. Similarly, certain strains of , such as B. adolescentis and B. pseudocatenulatum, actively synthesize (vitamin B9), an essential cofactor in one-carbon and , with production varying by strain and environmental conditions in the gut. These microbial vitamins can be absorbed by the host, supporting nutritional needs especially in diets low in these micronutrients. The microbiota also influences pharmacomicrobiomics, the field studying microbial impacts on drug metabolism and efficacy. Gut bacteria can directly biotransform pharmaceuticals; for example, inactivates the cardiac drug by reducing its ring via a cytochrome-encoding , thereby reducing its and therapeutic effect in a subset of individuals colonized by this strain. Additionally, microbial metabolites modulate host (CYP) enzymes, which are key in drug detoxification and metabolism, potentially altering pharmacokinetics of compounds like statins or analgesics. Such interactions highlight the microbiota's role in . Through these processes, the gut microbiota enhances host energy harvest from otherwise indigestible carbohydrates, contributing approximately 10% of daily caloric intake via SCFA production in Western diets. This energy extraction is modulated by microbial composition, with higher fermentative capacity linked to increased efficiency. Furthermore, microbiota-mediated deconjugation of bile acids—primarily by species like Bacteroides and Clostridium—hydrolyzes glycine or taurine conjugates, producing free bile acids that improve lipid emulsification and facilitate dietary fat absorption in the small intestine. This bile acid modification also influences enterohepatic circulation, optimizing fat-soluble nutrient uptake.30223-6)

Dysbiosis and Imbalances

Causes of Microbial Disruption

Microbial disruption, or , in the gut microbiota refers to alterations in microbial composition, diversity, and function that deviate from a healthy state, often triggered by medical interventions, physiological events, or environmental exposures. These disruptions can reduce beneficial taxa, promote overgrowth, and impair ecological niches, leading to imbalances that persist variably depending on the trigger. Antibiotics are among the most potent disruptors of gut microbiota, particularly broad-spectrum agents that deplete diverse bacterial populations. For instance, clindamycin administration rapidly reduces anaerobic bacteria and overall microbial diversity, with a single dose causing a profound loss of approximately 90% of phylotypes that endures for at least 28 days in a model. In humans, clindamycin induces profound and persistent changes in the fecal . This depletion creates opportunities for opportunistic pathogens like to overgrow, as the antibiotic selectively eliminates competing anaerobes while sparing spore-forming C. difficile. Recovery timelines vary; while some taxa like and rebound within weeks, full restoration can take months to years, with incomplete recovery observed up to 12 weeks post-treatment in many cases. Pregnancy induces estrogen-driven shifts in the maternal gut microbiota, contributing to through hormonal influences on microbial . Rising and progesterone levels, regulated by (hCG), alter gut composition, notably increasing the relative abundance of Proteobacteria while reducing overall . These changes extend to the vaginal microbiome, which fluctuates with cycles and can transmit microbes to the neonate during , seeding the infant's gut with a distinct microbial profile that may influence early-life risk. Such shifts support metabolic adaptations but can predispose to imbalances if exaggerated. Infections and associated further exacerbate by invading and reshaping microbial niches. or viruses trigger intestinal , which disrupts the stable microbial community structure and favors dominance over commensals. Enteric pathogens, for example, induce significant perturbations in microbiota composition during , altering resource availability and promoting that sustains . Medical treatments like and compound these effects; damages the intestinal barrier and mucus layer, leading to bacterial translocation and characterized by reduced beneficial and heightened susceptibility. Similarly, reduces protective taxa while enriching harmful ones, weakening gut integrity and amplifying inflammatory responses. Other factors, such as certain dietary additives and environmental toxins, also provoke through targeted metabolic interference. Artificial sweeteners like disrupt gut microbiota by altering pathways, including , and reducing microbial diversity in a sex-dependent manner. This interference can shift community structure toward inflammation-promoting profiles. Heavy metals, including , lead, and , induce by disturbing microbial composition and selecting for resistant strains; exposure enriches metal resistance genes in the gut , reducing overall diversity and favoring tolerant pathogens. Additionally, has been linked to gut and intestinal barrier disruption, as of 2025.

Consequences for Host Physiology

Dysbiosis in the gut microbiota disrupts the delicate balance of microbial communities, leading to profound alterations in host physiology through multiple interconnected pathways. This imbalance compromises the intestinal , dysregulates metabolic processes, skews immune responses, and promotes , ultimately contributing to widespread physiological dysfunction. These effects arise from the reduced diversity and altered composition of gut microbes, which impair their supportive roles in maintaining . One primary consequence is the breakdown of the intestinal barrier, often termed "leaky gut," where increases gut permeability. This heightened permeability allows bacterial components, such as lipopolysaccharides (LPS) from , to translocate into the bloodstream, triggering endotoxemia. Endotoxemia initiates a cascade of inflammatory responses that exacerbate tissue damage and systemic effects. For instance, studies have shown that dysbiotic shifts favor the overgrowth of LPS-producing , directly correlating with elevated circulating LPS levels and compromised integrity in the . Metabolic dysregulation represents another critical impact, particularly through diminished production of short-chain fatty acids (SCFAs) like butyrate and propionate, which are key microbial metabolites. Reduced SCFA levels impair insulin signaling pathways, contributing to and altered glucose . Additionally, modifies , leading to the accumulation of pro-inflammatory secondary bile acids that further promote metabolic and dysregulation. Research indicates that these changes disrupt energy harvest from diet and hepatic processing, amplifying physiological stress on metabolic organs. Immune imbalance is evident in the loss of regulatory T cells (Tregs), which normally suppress excessive immune responses, thereby heightening susceptibility to . Dysbiosis reduces Treg populations by altering microbial signals that promote their differentiation and maintenance. Concurrently, it enables the expansion of pathobionts, such as adherent-invasive (AIEC), which adhere to and invade epithelial cells, perpetuating local inflammation and immune dysregulation. This shift favors pro-inflammatory Th17 cells over tolerogenic responses, creating a feedback loop of immune hyperactivity. These local disruptions culminate in systemic effects, including chronic low-grade inflammation driven by elevated cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Translocated microbial products and inflammatory mediators disseminate via the bloodstream, inducing multi-organ dysfunction by activating innate immune pathways in distant tissues. This pervasive inflammation underlies broader physiological impairments, such as and , linking gut to holistic host compromise.

Associations with Disease

Gastrointestinal Pathologies

Dysbiosis of the gut plays a pivotal role in the of several gastrointestinal pathologies by disrupting microbial balance, promoting dominance, and exacerbating mucosal damage. In gastric ulcers, infection induces a profound shift in the gastric , characterized by reduced diversity and dominance of H. pylori, which erodes the protective mucosal layer through production and inflammatory responses. The surrounding , including opportunistic bacteria like and , further aids H. pylori persistence by modulating the local environment and suppressing beneficial taxa, thereby perpetuating chronic inflammation and ulcer formation. Inflammatory bowel diseases (IBD), encompassing and , are strongly associated with microbial , notably a consistent reduction in anti-inflammatory species such as Faecalibacterium prausnitzii. This depletion correlates with disease severity, as F. prausnitzii produces that maintain epithelial integrity; its absence heightens susceptibility to inflammation in both and patients. Additionally, dysbiotic stimulate the IL-23 pathway, where microbial antigens activate dendritic cells to produce IL-23, driving Th17 cell differentiation and pro-inflammatory cytokine release that amplifies intestinal barrier dysfunction and chronic . Irritable bowel syndrome (IBS) involves altered gut microbiota composition, particularly shifts in methane-producing archaea, which contribute to symptomology including visceral . In constipation-predominant IBS, elevated levels of methanogens like Methanobrevibacter smithii increase production, slowing gut transit and distending the intestinal wall, which sensitizes nociceptors and heightens to normal stimuli. This dysbiosis-induced is further linked to reduced butyrate producers, impairing mucosal protection and amplifying IBS symptoms. Diverticulitis arises from dysbiosis in colonic , where weakened diverticular walls allow opportunistic overgrowth, leading to localized and risk of . Studies show enriched opportunistic taxa, such as Clostridium bolteae and Clostridium clostridioforme, in diverticulitis patients, which exploit mucosal breaches to invade tissues and provoke acute infection. This microbial imbalance reduces protective Firmicutes and promotes Proteobacteria expansion, exacerbating complications like abscess formation or bowel in susceptible individuals.

Systemic and Metabolic Disorders

The gut plays a pivotal role in the development of through alterations in microbial composition that enhance energy extraction from the diet. In obese individuals, the relative abundance of Firmicutes increases while Bacteroidetes decreases, resulting in a higher Firmicutes/Bacteroidetes ratio that correlates with greater caloric harvest from otherwise indigestible . This dysbiotic shift has been observed in both human cohorts and germ-free mouse models colonized with microbiota from obese donors, where the transplanted microbiota promotes weight gain and adiposity. Furthermore, depletion of beneficial taxa such as , a mucin-degrading bacterium, is consistently associated with , as its reduced presence impairs gut barrier integrity and exacerbates metabolic inflammation. Supplementation with live or pasteurized A. muciniphila in preclinical models reverses diet-induced obesity by improving gut permeability and insulin sensitivity. Dysbiosis in the gut microbiota also contributes to both type 1 and type 2 by promoting low-grade and impairing pancreatic beta-cell function. In type 2 , increased translocation of (LPS) from across a leaky gut barrier induces metabolic endotoxemia, triggering 4-mediated that fosters . This mechanism is evidenced in high-fat diet-fed mice, where disruption of the reduces LPS levels and ameliorates . For type 1 , an autoimmune condition, early-life characterized by reduced microbial diversity and overgrowth of pro-inflammatory taxa accelerates beta-cell destruction via innate immune dysregulation, as demonstrated in non-obese diabetic ( where transfer from protected strains prevents disease onset. Additionally, deficiency in like butyrate, produced by fermentative bacteria such as Faecalibacterium prausnitzii, impairs beta-cell survival and insulin secretion; butyrate supplementation in diabetic models enhances beta-cell proliferation and protects against cytokine-induced through inhibition and pathways. In metabolic syndrome, a cluster of conditions including , , and central , gut microbiota-derived metabolites exacerbate cardiovascular risk. Microbial metabolism of dietary choline and by taxa such as produces N-oxide (TMAO), which promotes formation and by enhancing uptake in macrophages and platelet hyperreactivity. Plasma TMAO levels are elevated in patients with metabolic syndrome and predict , with germ-free mice fed TMAO precursors showing accelerated plaque development upon microbiota reconstitution. This pathway underscores the microbiota's role in linking dietary patterns to systemic vascular pathology. Early-life gut dysbiosis has been implicated in the pathogenesis of , a systemic allergic disorder, through reduced microbial diversity that skews immune development toward Th2 dominance. Infants with low gut microbiota diversity in the first month of life exhibit a higher risk of asthma diagnosis at school age, independent of or rhinoconjunctivitis, as low alpha-diversity correlates with impaired regulatory T-cell induction and increased allergic sensitization.01582-8/fulltext) Longitudinal cohort studies confirm that cesarean delivery and antibiotic exposure, which diminish early diversity, precede asthma onset, highlighting a critical window for microbiota-immune in respiratory health.01582-8/fulltext)

Neurological and Immune-Mediated Conditions

The gut-brain axis represents a bidirectional communication pathway between the and the , mediated in part by vagal sensory neurons that transmit signals from gut microbiota-derived metabolites and immune factors to the . This axis influences neurological function through neural, endocrine, and immune routes, with —imbalances in microbial composition—disrupting these signals and contributing to various disorders. A key mechanism involves serotonin production, where approximately 95% of the body's serotonin is synthesized in the gut by enterochromaffin cells entrained by microbial cues, such as (SCFAs) from bacterial , which modulate mood and gastrointestinal motility. Alterations in this production due to microbiota shifts can exacerbate neuroinflammatory responses and behavioral changes. In neurodegenerative conditions like (PD), gut promotes the aggregation of , a protein central to disease pathology, potentially initiating a prion-like spread from the to the brain via the . Studies in germ-free mouse models demonstrate that absence of reduces accumulation and motor deficits, while colonization with gut or specific bacteria like those producing curli amyloids promotes aggregation and exacerbates symptoms.31590-2) Similarly, in (AD), correlates with reduced SCFA levels, which normally suppress by inhibiting microglial activation and amyloid-beta plaque formation; supplementation with SCFAs like butyrate has shown protective effects in preclinical models by modulating activity in the brain. These findings underscore how microbial metabolites influence protein misfolding and inflammatory cascades in the . Autoimmune disorders, including (T1D) and (MS), are linked to microbiota-driven breakdowns in intestinal barrier integrity, often termed "leaky gut," which allows luminal antigens to trigger aberrant immune responses. In T1D, impairs regulatory T-cell (Treg) induction by reducing SCFA-mediated signaling through G-protein-coupled receptors, leading to unchecked autoreactive T-cells that target pancreatic beta cells; early-life microbial exposures have been shown to prevent this in non-obese diabetic mouse models. For MS, leaky gut facilitates the escape of myelin-reactive T-cells into systemic circulation, exacerbated by decreased abundance of Treg-promoting bacteria like species, resulting in demyelination and ; fecal microbiota transplantation from healthy donors has ameliorated symptoms in experimental autoimmune models by restoring . These mechanisms highlight the microbiota's role in priming and preventing central nervous system . Psychiatric conditions such as depression and anxiety exhibit strong correlations with reduced levels of and genera, which produce gamma-aminobutyric acid (GABA) and other neuromodulators that dampen hypothalamic-pituitary-adrenal axis hyperactivity. Meta-analyses of clinical trials indicate that supplementation with these strains significantly alleviates depressive symptoms, with effect sizes comparable to antidepressants in mild cases, likely via enhanced serotonin signaling and reduced cytokine-mediated inflammation. Post-2020 research on survivors has further illuminated these links, revealing that SARS-CoV-2-induced gut persists in patients, correlating with heightened anxiety and depression through disrupted microbiota-gut-brain axis signaling, including vagal efferent dysfunction and elevated neuroinflammatory markers. These associations suggest microbiota modulation as a potential adjunctive for psychiatric resilience following viral insults.

Interventions and Therapies

Probiotic and Prebiotic Strategies

Probiotics are live microorganisms, such as specific strains of Lactobacillus and Bifidobacterium, administered in adequate amounts to confer health benefits on the host by modulating the gut microbiota. These benefits arise through mechanisms including competitive exclusion of pathogens, enhancement of intestinal barrier integrity, and immunomodulation via cytokine regulation and immune cell activation. For instance, Lactobacillus rhamnosus GG (LGG) adheres to intestinal epithelial cells, inhibits pathogen adhesion, and promotes mucin production to reduce diarrhea incidence, particularly in children and antibiotic-associated cases. Similarly, multi-strain formulations like VSL#3, containing eight bacterial species including Streptococcus thermophilus and various Bifidobacterium strains, demonstrate strain-specific efficacy in inducing and maintaining remission in mild-to-moderate ulcerative colitis, a form of inflammatory bowel disease (IBD), by downregulating pro-inflammatory pathways. Prebiotics are non-digestible food substrates, such as and fructo-oligosaccharides (FOS), that are selectively fermented by beneficial gut microbes to produce (SCFAs) like butyrate, which nourish colonocytes and modulate . These compounds preferentially stimulate the growth of Bifidobacterium species, enhancing microbial diversity and SCFA production while suppressing opportunistic pathogens. The International Scientific Association for Probiotics and Prebiotics (ISAPP) defines prebiotics as substrates conferring health benefits through selective microbial utilization. Synbiotics combine and prebiotics to synergistically improve microbial survival and colonization, amplifying benefits such as enhanced gut barrier function and immune modulation beyond those of individual components. For example, pairing strains with FOS increases bifidogenic effects and SCFA yields in the colon. Clinical evidence supports and prebiotic use for gut-related conditions. Meta-analyses indicate that alleviate (IBS) symptoms, including and , with multi-strain products showing moderate efficacy in global symptom scores compared to . Strain-specific trials, such as those with VSL#3, report up to 40% higher remission rates in active when added to standard mesalamine therapy. Prebiotics like improve IBS outcomes by increasing abundance and reducing transit time. Probiotics and prebiotics are (GRAS) by the U.S. for most healthy populations, based on historical use and extensive safety data for strains like and , though immunocompromised individuals require caution. By 2025, postbiotics—non-viable microbial products or metabolites like inactivated cells and SCFAs—have emerged as a safer alternative, offering similar immunomodulatory and anti-inflammatory benefits without live organism risks, with ongoing research highlighting their role in gut barrier reinforcement.

Advanced Microbiome Therapies

Fecal microbiota transplantation (FMT) involves the transfer of fecal matter from a healthy donor to a recipient to restore a balanced gut , primarily used for treating recurrent (rCDI). Although FMT was initially classified as investigational by the FDA in 2013, allowing its use under protocols for rCDI, the first fully approved product, Rebyota (fecal microbiota, live-jslm), received FDA approval in 2022 for preventing recurrence in adults following treatment. Clinical protocols for FMT include delivery via , which enables direct infusion into the colon for potentially higher engraftment, or oral capsules containing freeze-dried donor material, such as Vowst (fecal microbiota spores, live-brpk; approved by FDA in 2023 as the first oral product), offering a non-invasive alternative with comparable microbial transfer. Overall efficacy for resolving rCDI reaches approximately 90% after a single treatment, significantly outperforming repeated courses that yield only 60% success for subsequent recurrences. Phage therapy employs bacteriophages—viruses that specifically infect and lyse targeted —to modulate the gut microbiota without broadly disrupting commensal populations. In the context of (IBD), phages are designed to eliminate pathobionts such as adherent-invasive , reducing inflammation in preclinical models of . Clinical trials in the have advanced this approach, with phase I/II studies demonstrating safety and preliminary efficacy in IBD patients by achieving targeted bacterial reduction and improved endoscopic scores, though larger randomized trials are ongoing to confirm long-term benefits. These therapies highlight phages' precision, minimizing off-target effects compared to broad-spectrum antibiotics. Engineered bacteria leverage to create with tailored functions for restoration, often using safe strains like Nissle 1917 (EcN). For instance, EcN has been modified to express anti-inflammatory cytokines such as interleukin-10, enabling localized suppression of gut inflammation in IBD models by sensing disease markers and releasing therapeutics in situ. CRISPR-Cas9 editing further enhances precision, allowing targeted gene insertions for improved colonization, metabolite production, or resistance, as demonstrated in engineered EcN variants that persist in the gut and modulate immune responses. These advancements, validated in and early human trials, position engineered microbes as next-generation interventions for chronic . Pharmabiotics represent hybrid approaches combining microbial agents with pharmaceutical properties, including live biotherapeutics designed for specific metabolic modulation. In management, 2025 updates highlight live biotherapeutics derived from gut bacteria that produce peptides regulating glucose and reducing fat accumulation, as shown in preclinical models where strains lowered body weight by 10-15% through enhanced gut barrier integrity and appetite suppression. Clinical pipelines now include FDA-designated live biotherapeutic products targeting via microbiota engineering, with phase II trials reporting sustained and improved insulin sensitivity, underscoring their potential as adjuncts to interventions.

Dietary and Lifestyle Approaches

Dietary approaches play a pivotal role in fostering a healthy gut microbiota composition. The , characterized by high intake of fruits, , whole grains, , nuts, and , has been shown to enhance microbial diversity through its rich content of and polyphenols. These components serve as substrates for beneficial bacteria, promoting the growth of short-chain fatty acid (SCFA)-producing taxa such as and . Studies indicate that adherence to this dietary pattern correlates with increased in the gut , which is associated with improved metabolic health. Similarly, plant-based diets (PBDs), emphasizing a variety of plant foods, support microbiota diversity by providing fermentable fibers that favor the proliferation of fiber-degrading microbes, leading to elevated SCFA production and reduced inflammation markers. Long-term PBD consumption has been linked to shifts toward anti-inflammatory microbial profiles, including higher abundances of and . Incorporating fermented foods into the diet offers another avenue for microbiota modulation. Foods such as and introduce live microorganisms that can transiently colonize the gut, potentially enhancing overall microbial resilience. Consumption of these products has been observed to increase the abundance of and modulate immune responses via microbiota-immune interactions, with effects persisting beyond the transient presence of the ingested strains. For instance, regular intake of fermented and correlates with elevated levels of beneficial taxa like species, contributing to a more balanced ecosystem. Lifestyle practices, including , further support microbiota health. This eating pattern, involving cycles of feeding and fasting, promotes the renewal of the intestinal layer and enriches mucin-associated such as , which is inversely associated with metabolic disorders. Research demonstrates that intermittent fasting regimens, such as time-restricted eating, lead to increased microbial diversity and abundance of SCFA producers, partly by altering metabolism and reducing gut permeability. Islamic fasting, a form of intermittent fasting, specifically boosts levels, underscoring its role in maintaining mucosal integrity. Physical exercise represents a modifiable factor influencing the gut microbiota. Moderate-intensity activities, such as , are associated with increased populations of butyrate-producing bacteria, including Roseburia and prausnitzii, which generate SCFAs that strengthen the gut barrier and reduce . Systematic reviews confirm that regular moderate exercise elevates fecal butyrate concentrations and enhances overall microbial diversity, with effects more pronounced in structured programs. Complementing this, adequate mitigates stress-induced ; chronic disrupts microbial balance by favoring pro-inflammatory taxa and reducing diversity, whereas sufficient restorative sleep preserves beneficial communities and attenuates stress-related shifts in microbiota composition. Avoiding certain dietary elements is equally important for preservation. Limiting intake of ultra-processed foods, which often contain additives like emulsifiers, helps prevent disruptions to microbial and community structure. Emulsifiers such as (P80) have been shown to promote low-grade by altering composition, increasing the abundance of colitogenic like Proteobacteria while decreasing SCFA producers. Mouse models reveal that P80 exposure induces gut , , and enhanced susceptibility to , highlighting the need to minimize such compounds to maintain integrity and microbial .

Research Frontiers

Analytical Methods and Technologies

The study of gut microbiota composition and function relies on a suite of analytical methods that have evolved to capture the complexity of microbial communities. remains a cornerstone for taxonomic profiling, targeting hypervariable regions of the bacterial to identify operational taxonomic units (OTUs) at the genus or level. This amplicon-based approach enables high-throughput analysis of bacterial diversity in fecal samples, though it is limited to prokaryotes and cannot resolve functional potential directly. For instance, full-length has improved resolution of strain-level variations in the human gut microbiome by detecting single-nucleotide polymorphisms. Shotgun metagenomics complements 16S sequencing by providing a culture-independent view of both and function through random fragmentation and sequencing of total from microbial communities. This method reconstructs metagenome-assembled genomes (MAGs) and annotates functional genes, often mapping them to databases like to infer metabolic pathways such as degradation or in the gut. Studies using shotgun have revealed heritable functional modules in the gut , including those linked to host nutrition and immune modulation. Culturomics addresses the limitations of sequencing by employing high-throughput anaerobic culturing techniques to isolate and characterize viable microbes that may be underrepresented in data. Developed as a revival of culture-based methods, culturomics uses matrix-assisted desorption/ionization-time of flight (MALDI-TOF MS) for rapid identification and tests hundreds of growth conditions to recover novel from the gut. For example, metagenome-guided culturomics integrates prior sequencing data to target specific taxa, enhancing the recovery of fastidious anaerobes like those in the Firmicutes . Metabolomics techniques, particularly liquid chromatography-mass spectrometry (LC-MS), are essential for quantifying microbiota-derived metabolites that influence host physiology. LC-MS-based profiling detects (SCFAs) such as butyrate and acetate, as well as secondary bile acids like , which are produced via microbial of dietary fibers and bile salt modification. Derivatization strategies with agents like 3-nitrophenylhydrazine (3-NPH) improve sensitivity for simultaneous measurement of SCFAs, bile acids, and other gut metabolites in fecal samples. Fluxomics extends this by modeling dynamic metabolic fluxes using stable isotope tracing and constraint-based approaches like (FBA), revealing temporal changes in microbiota-host interactions such as SCFA production rates. As of 2025, technologies have advanced the resolution of gut microbiota analysis, enabling transcriptomic profiling of individual microbial cells within complex communities. High-throughput single-microbe sequencing has uncovered adaptive patterns in gut , such as stress responses in genera like and , by depleting rRNA and sequencing polyadenylated transcripts. These methods, often combined with , facilitate the study of rare subpopulations and their functional heterogeneity in the gut niche. Artificial intelligence and machine learning (AI/ML) models have emerged as powerful tools for predictive modeling of gut , integrating multi-omics data to forecast microbial shifts and their health implications. algorithms analyze longitudinal metagenomic datasets to predict patterns associated with conditions like , achieving high accuracy in identifying key taxa drivers through feature extraction and generative modeling. Interpretable ML approaches, such as those using SHAP values, further elucidate causal relationships in dynamics, enabling personalized predictions of responses to perturbations. In November 2025, neural networks were used to explore large gut microbe datasets, revealing hidden communication patterns among microbes that provide clues to health impacts.

Emerging Insights and Future Directions

Recent studies post-2020 have illuminated the gut microbiota's involvement in , revealing persistent characterized by reduced microbial diversity and altered bacterial composition that correlates with ongoing symptoms such as and gastrointestinal distress up to one year after . Emerging also suggests potential virome persistence in some cases, with viral elements in the gut potentially contributing to prolonged via interactions with the bacterial , though direct viral detection in stool remains infrequent. Recent discoveries in October 2025 identified hundreds of new bacteriophages in the human gut, opening new avenues for studying viral-bacterial interactions and developing microbiome-based therapies. In , species have been shown to enhance the efficacy of inhibitors by promoting antitumor immune responses, including increased CD8+ T-cell infiltration into tumors through metabolite production like . Advancements in leverage gut profiling for diagnostics, such as predicting (IBS) subtypes through models that identify microbial signatures like reduced abundance as early biomarkers. These approaches extend to AI-driven interventions, where algorithms analyze data to tailor diets that optimize microbial diversity and reduce inflammation, demonstrating improved gut health outcomes in pilot trials. Despite these insights, establishing causality in microbiota-disease associations remains challenging, as observational data often confounds with causation, necessitating advanced methods like to disentangle effects. Ethical concerns in fecal transplantation (FMT) further complicate progress, particularly around donor screening for pathogens, for vulnerable recipients, and equitable access to therapies. Looking ahead, offers promising avenues for modulation, with micro/nanorobots designed for targeted delivery in the to selectively alter microbial communities and enhance therapeutic precision. Studies on space travel highlight the need for stability research, as microgravity and isolation induce that accelerates immune aging, informing strategies for long-duration missions. Additionally, as of November 2025, research has shown that non-absorbed antibiotics can stimulate gut to produce compounds promoting , suggesting novel -targeted interventions for aging.

Comparative Aspects

Microbiota in Non-Human Animals

The gut microbiota in non-human animals exhibits remarkable diversity shaped by dietary adaptations, ecological niches, and host physiology, often paralleling aspects of human microbial composition such as the dominance of Firmicutes and Bacteroidetes in mammals. In herbivorous mammals like ruminants, the rumen harbors specialized cellulolytic consortia dominated by bacteria such as Fibrobacter and Ruminococcus species, which ferment plant polysaccharides into volatile fatty acids essential for energy extraction from fibrous diets. These microbial communities enable efficient lignocellulose breakdown, a process absent in monogastric herbivores, highlighting evolutionary adaptations to herbivory. In contrast, carnivorous mammals maintain low-diversity gut microbiomes, characterized by higher abundances of Proteobacteria and Fusobacteria alongside relatively lower proportions of Firmicutes and Bacteroidetes compared to herbivores, reflecting their protein- and fat-rich diets that require minimal fiber fermentation. In , symbiotic gut microbiota support specialized functions tied to and . Honeybees (Apis mellifera) host a core including species that aid in processing and provide antimicrobial protection, thereby enhancing host nutrition and immunity critical for activities. Similarly, rely on a multifaceted gut involving bacteria like and for lignocellulose degradation, where microbial enzymes hydrolyze wood components into fermentable sugars, sustaining the colony's wood-feeding lifestyle. These insect microbiomes underscore the role of host-microbe partnerships in acquisition from recalcitrant substrates. Model organisms such as facilitate research due to partial transferability to human systems. gut communities, when humanized via fecal transplantation into germ-free recipients, can stably engraft human-like taxa and recapitulate metabolic responses, though differences in diet and physiology limit full equivalence. Gnotobiotic animals, raised under axenic conditions and selectively colonized, enable by isolating microbial effects on host phenotypes, such as immune development or resistance. Zoonotic implications arise from animal microbiomes serving as reservoirs for pathogens that disrupt microbial balance. In , Salmonella enterica serovars colonize the , altering native composition and facilitating transmission to humans via contaminated food, with non-typhoidal strains posing significant risks. This highlights the need to monitor animal gut ecosystems for preventing cross-species pathogen spillover.

Evolutionary Perspectives

The evolutionary history of gut microbiota traces back to the ancient origins of microbial life on , with evidence of microbial fossils preserved in dating to approximately 3.5 billion years ago, representing some of the earliest known prokaryotic communities that laid the foundation for symbiotic relationships. These ancient microbial mats, formed by and other , demonstrate the long-standing capacity of microbes to form structured communities, which later evolved into symbiotic associations with eukaryotic hosts. In early metazoans, such as s (phylum Porifera), which emerged around 600-800 million years ago during the period, host-microbe symbioses became prominent, with microbes comprising up to 30% of sponge and contributing to and structural integrity. This partnership exemplifies one of the earliest documented instances of mutualistic interactions, where microbes facilitated the ecological success of these basal animals by providing metabolic support in nutrient-poor environments. Co-evolution between gut microbiota and hosts has proceeded through diverse transmission mechanisms and genetic exchanges, shaping host physiology across taxa. In insects, vertical transmission—where microbiota are passed directly from mother to offspring via eggs—promotes co-speciation and stability of core microbial consortia, as seen in species like aphids and termites, enabling specialized functions such as cellulose digestion. Conversely, in mammals, horizontal transmission predominates, involving acquisition of microbes from the environment and conspecifics during birth and social interactions, which fosters microbial diversity but allows for adaptive flexibility in response to dietary or ecological shifts. Horizontal gene transfer (HGT) further drives co-evolution, with bacteria transferring genes to eukaryotic hosts; for instance, genes involved in lipid metabolism and detoxification in animals have bacterial origins, potentially acquired through ancient endosymbiotic events in the gut niche. These mechanisms highlight how microbiota have integrated into host genomes and life cycles, enhancing resilience and innovation in host evolution. In , significant shifts in gut microbiota composition occurred with major dietary transitions, notably the around 10,000 years ago, when the adoption of and domesticated grains led to reduced microbial diversity compared to ancestors. Analysis of ancient dental calculus from European populations reveals a gradual replacement of diverse forager-associated taxa with specialized fermenters adapted to starch-rich diets, mirroring broader gut microbiota changes inferred from modern comparisons. More recently, the posits that intensified sanitation and reduced microbial exposure since the represent a rapid evolutionary mismatch, diminishing early-life colonization by beneficial bacteria and contributing to immune dysregulation. This perspective frames modern hygiene practices as a selective pressure altering microbiota-host co-adaptation, with implications for and autoimmune prevalence. Despite these variations, core functions of gut microbiota remain highly conserved across phyla, underscoring their fundamental role in host . For example, the production of (SCFAs) such as , propionate, and butyrate—derived from —provides energy to host cells, modulates , and supports epithelial barrier integrity, a capability shared among Firmicutes and Bacteroidetes in vertebrates, , and even some non-metazoan hosts. This preservation of metabolic pathways, evident from comparative genomic studies, illustrates how ancient symbiotic innovations have endured, enabling hosts to exploit diverse niches while maintaining metabolic .

References

Add your contribution
Related Hubs
User Avatar
No comments yet.